<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421352</url>
  </required_header>
  <id_info>
    <org_study_id>CS1001-101-13</org_study_id>
    <nct_id>NCT04421352</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients</brief_title>
  <official_title>A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with
      CS1001 in relapsed SCLC patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dose-escalation study of Low-dose Radiation in combination with CS1001 in relapsed
      SCLC patients. Patients are assigned to 3 treatment groups received from 3 Gy to 15Gy, to
      determine the safety, tolerability and the maximal tolerant dose. Biomarkers and
      immunological markers are collected and analyzed as well.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of CS1001</measure>
    <time_frame>From first dose to 30 days after last dose of CS1001, up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate as Determined by the Investigator Using RECIST v1.1</measure>
    <time_frame>From first dose to 30 days after last dose of CS1001, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>From first dose to 30 days after last dose of CS1001, up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first dose to 30 days after last dose of CS1001, up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Relapsed Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>low-dose radiation+CS1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose radiation+CS1001</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1001</intervention_name>
    <description>low-dose radiation+CS1001 1200mg Q3W. In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
Dose A: 3Gy/1f; Dose B: 9Gy/3f; Dose C: 15Gy/5f;
In the dose expansion part, more SCLC patients will be assigned.</description>
    <arm_group_label>low-dose radiation+CS1001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with histologically or cytologically confirmed LS-SCLC or ES-SCLC and
             experienced progression since first-line standard platinum containing dual-drug
             chemotherapy; first-line standard therapy is not available or rejected.

          2. Patients whose initial diagnosis was limited must undergo radical chest radiotherapy
             and the time of tumor progression is not less than 3 months from the end of
             radiotherapy, or cannot receive radical chest radiotherapy due to specific reasons

          3. At least one extracranial measurable lesion (RECIST v1.1), and for a lesion that has
             received radiotherapy, progression of the lesion after radiotherapy must be confirmed.

          4. Patients with brain metastases are allowed to receive previous radiotherapy and their
             condition is stable, but the time to the end of radiotherapy must not be less than 3
             months.

          5. No radiotherapy contraindications were judged by the radiologist

          6. ECOG performance status of 0 or 1.

          7. Patients must have at least one measurable lesion.

          8. Patients with life expectancy ≥ 3 months.

          9. Patients must have adequate organ function.

         10. Fertile men and women of childbearing potential must agree to use an effective method
             of birth control from providing signed consent and for 180 days after last study drug
             administration.

        Exclusion Criteria:

          1. Known brain metastasis or other CNS metastasis that is either symptomatic or
             untreated.

          2. Patients with active autoimmune diseases or history of autoimmune diseases should be
             excluded.

          3. Patients who have received immune checkpoint proteins/antibody/medicine (including
             PD-1, PD-L1, etc) for treatment.

          4. Known history of HIV infection.

          5. Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) positive or
             Hepatitis C virus (HCV) antibody positive.

          6. Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the
             exception of vitiligo, alopecia.

          7. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have
             history of uncontrolled allergic asthma.

          8. Known history of alcoholism or drugs abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>You Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendie Yuan</last_name>
    <phone>+86 21 61097678</phone>
    <email>cstonera@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>You Lu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV; IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.</citation>
    <PMID>30280641</PMID>
  </results_reference>
  <results_reference>
    <citation>Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, Eder JP, Steele NL, Pieters A, Fairchild J, Antonia SJ. Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019 Feb;14(2):237-244. doi: 10.1016/j.jtho.2018.10.003. Epub 2018 Oct 10.</citation>
    <PMID>30316010</PMID>
  </results_reference>
  <results_reference>
    <citation>Li LY, Wang H, Chen X, Li WQ, Cui JW. First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China. Chin Med J (Engl). 2019 Dec 5;132(23):2790-2794. doi: 10.1097/CM9.0000000000000536.</citation>
    <PMID>31856049</PMID>
  </results_reference>
  <results_reference>
    <citation>Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.</citation>
    <PMID>31590988</PMID>
  </results_reference>
  <results_reference>
    <citation>Yin L, Xue J, Li R, Zhou L, Deng L, Chen L, Zhang Y, Li Y, Zhang X, Xiu W, Tong R, Gong Y, Huang M, Xu Y, Zhu J, Yu M, Li M, Lan J, Wang J, Mo X, Wei Y, Niedermann G, Lu Y. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 May 15. pii: S0360-3016(20)31126-3. doi: 10.1016/j.ijrobp.2020.05.002. [Epub ahead of print]</citation>
    <PMID>32417411</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

